Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
Identifieur interne : 000631 ( PascalFrancis/Corpus ); précédent : 000630; suivant : 000632Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
Auteurs : Nancy E. Thomas ; Klaus J. Busam ; Lynn From ; Anne Kricker ; Bruce K. Armstrong ; Hoda Anton-Culver ; Stephen B. Gruber ; Richard P. Gallagher ; Roberto Zanetti ; Stefano Rosso ; Terence Dwyer ; Alison Venn ; Peter A. Kanetsky ; Pamela A. Groben ; HONGLIN HAO ; Irene Orlow ; Anne S. Reiner ; LI LUO ; Susan Paine ; David W. Ollila ; Homer Wilcox ; Colin B. Begg ; Marianne BerwickSource :
- Journal of clinical oncology [ 0732-183X ] ; 2013.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Purpose Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. Patients and Methods On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined. Results Independent predictors (P< .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (Ptrend < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage. Conclusion At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 14-0010513 INIST |
|---|---|
| ET : | Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study |
| AU : | THOMAS (Nancy E.); BUSAM (Klaus J.); FROM (Lynn); KRICKER (Anne); ARMSTRONG (Bruce K.); ANTON-CULVER (Hoda); GRUBER (Stephen B.); GALLAGHER (Richard P.); ZANETTI (Roberto); ROSSO (Stefano); DWYER (Terence); VENN (Alison); KANETSKY (Peter A.); GROBEN (Pamela A.); HONGLIN HAO; ORLOW (Irene); REINER (Anne S.); LI LUO; PAINE (Susan); OLLILA (David W.); WILCOX (Homer); BEGG (Colin B.); BERWICK (Marianne) |
| AF : | University of North Carolina/Chapel Hill, NC/Etats-Unis (1 aut., 14 aut., 15 aut., 20 aut.); Memorial Sloan-Kettering Cancer Center/New York, NY/Etats-Unis (2 aut., 16 aut., 17 aut., 22 aut.); Women's College Hospital/Toronto, Ontario/Canada (3 aut.); British Columbia Cancer Research Centre/Vancouver, British Columbia/Canada (8 aut.); The University of Sydney/Sydney, New South Wales/Australie (4 aut., 5 aut.); Menzies Research Institute/Tasmania/Australie (12 aut.); University of California/Irvine/Etats-Unis (6 aut.); University of Southern California/Los Angeles, CA/Etats-Unis (7 aut.); Center for Cancer Prevention/Torino/Italie (9 aut., 10 aut.); International Agency for Research on Cancer/Lyon/France (11 aut.); University of Pennsylvania/Philadelphia, PA/Etats-Unis (13 aut.); University of New Mexico/Albuquerque, NM/Etats-Unis (18 aut., 19 aut., 23 aut.); New Jersey Department of Health/Trenton, NJ/Etats-Unis (21 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Journal of clinical oncology; ISSN 0732-183X; Etats-Unis; Da. 2013; Vol. 31; No. 33; Pp. 4252-4259; Bibl. 34 ref. |
| LA : | Anglais |
| EA : | Purpose Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. Patients and Methods On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined. Results Independent predictors (P< .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (Ptrend < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage. Conclusion At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions. |
| CC : | 002B04C; 002B08A |
| FD : | Mélanome malin; Lymphocyte infiltrant tumeur; Primaire; Association; Origine ethnique; Survie; Gène; Génétique; Environnement; Cancérologie |
| FG : | Tumeur maligne; Cancer |
| ED : | Malignant melanoma; Tumor infiltrating lymphocyte; Primary; Association; Ethnic origin; Survival; Gene; Genetics; Environment; Cancerology |
| EG : | Malignant tumor; Cancer |
| SD : | Melanoma maligno; Linfocito infiltrando tumor; Primario; Asociación; Origen étnico; Sobrevivencia; Gen; Genética; Medio ambiente; Cancerología |
| LO : | INIST-20094.354000507427000120 |
| ID : | 14-0010513 |
Links to Exploration step
Pascal:14-0010513Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study</title><author><name sortKey="Thomas, Nancy E" sort="Thomas, Nancy E" uniqKey="Thomas N" first="Nancy E." last="Thomas">Nancy E. Thomas</name><affiliation><inist:fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Busam, Klaus J" sort="Busam, Klaus J" uniqKey="Busam K" first="Klaus J." last="Busam">Klaus J. Busam</name><affiliation><inist:fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="From, Lynn" sort="From, Lynn" uniqKey="From L" first="Lynn" last="From">Lynn From</name><affiliation><inist:fA14 i1="03"><s1>Women's College Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kricker, Anne" sort="Kricker, Anne" uniqKey="Kricker A" first="Anne" last="Kricker">Anne Kricker</name><affiliation><inist:fA14 i1="05"><s1>The University of Sydney</s1><s2>Sydney, New South Wales</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Armstrong, Bruce K" sort="Armstrong, Bruce K" uniqKey="Armstrong B" first="Bruce K." last="Armstrong">Bruce K. Armstrong</name><affiliation><inist:fA14 i1="05"><s1>The University of Sydney</s1><s2>Sydney, New South Wales</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Anton Culver, Hoda" sort="Anton Culver, Hoda" uniqKey="Anton Culver H" first="Hoda" last="Anton-Culver">Hoda Anton-Culver</name><affiliation><inist:fA14 i1="07"><s1>University of California</s1><s2>Irvine</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gruber, Stephen B" sort="Gruber, Stephen B" uniqKey="Gruber S" first="Stephen B." last="Gruber">Stephen B. Gruber</name><affiliation><inist:fA14 i1="08"><s1>University of Southern California</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gallagher, Richard P" sort="Gallagher, Richard P" uniqKey="Gallagher R" first="Richard P." last="Gallagher">Richard P. Gallagher</name><affiliation><inist:fA14 i1="04"><s1>British Columbia Cancer Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zanetti, Roberto" sort="Zanetti, Roberto" uniqKey="Zanetti R" first="Roberto" last="Zanetti">Roberto Zanetti</name><affiliation><inist:fA14 i1="09"><s1>Center for Cancer Prevention</s1><s2>Torino</s2><s3>ITA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rosso, Stefano" sort="Rosso, Stefano" uniqKey="Rosso S" first="Stefano" last="Rosso">Stefano Rosso</name><affiliation><inist:fA14 i1="09"><s1>Center for Cancer Prevention</s1><s2>Torino</s2><s3>ITA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dwyer, Terence" sort="Dwyer, Terence" uniqKey="Dwyer T" first="Terence" last="Dwyer">Terence Dwyer</name><affiliation><inist:fA14 i1="10"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Venn, Alison" sort="Venn, Alison" uniqKey="Venn A" first="Alison" last="Venn">Alison Venn</name><affiliation><inist:fA14 i1="06"><s1>Menzies Research Institute</s1><s2>Tasmania</s2><s3>AUS</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kanetsky, Peter A" sort="Kanetsky, Peter A" uniqKey="Kanetsky P" first="Peter A." last="Kanetsky">Peter A. Kanetsky</name><affiliation><inist:fA14 i1="11"><s1>University of Pennsylvania</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Groben, Pamela A" sort="Groben, Pamela A" uniqKey="Groben P" first="Pamela A." last="Groben">Pamela A. Groben</name><affiliation><inist:fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Honglin Hao" sort="Honglin Hao" uniqKey="Honglin Hao" last="Honglin Hao">HONGLIN HAO</name><affiliation><inist:fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Orlow, Irene" sort="Orlow, Irene" uniqKey="Orlow I" first="Irene" last="Orlow">Irene Orlow</name><affiliation><inist:fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Reiner, Anne S" sort="Reiner, Anne S" uniqKey="Reiner A" first="Anne S." last="Reiner">Anne S. Reiner</name><affiliation><inist:fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Li Luo" sort="Li Luo" uniqKey="Li Luo" last="Li Luo">LI LUO</name><affiliation><inist:fA14 i1="12"><s1>University of New Mexico</s1><s2>Albuquerque, NM</s2><s3>USA</s3><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Paine, Susan" sort="Paine, Susan" uniqKey="Paine S" first="Susan" last="Paine">Susan Paine</name><affiliation><inist:fA14 i1="12"><s1>University of New Mexico</s1><s2>Albuquerque, NM</s2><s3>USA</s3><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ollila, David W" sort="Ollila, David W" uniqKey="Ollila D" first="David W." last="Ollila">David W. Ollila</name><affiliation><inist:fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Wilcox, Homer" sort="Wilcox, Homer" uniqKey="Wilcox H" first="Homer" last="Wilcox">Homer Wilcox</name><affiliation><inist:fA14 i1="13"><s1>New Jersey Department of Health</s1><s2>Trenton, NJ</s2><s3>USA</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Begg, Colin B" sort="Begg, Colin B" uniqKey="Begg C" first="Colin B." last="Begg">Colin B. Begg</name><affiliation><inist:fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Berwick, Marianne" sort="Berwick, Marianne" uniqKey="Berwick M" first="Marianne" last="Berwick">Marianne Berwick</name><affiliation><inist:fA14 i1="12"><s1>University of New Mexico</s1><s2>Albuquerque, NM</s2><s3>USA</s3><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0010513</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 14-0010513 INIST</idno><idno type="RBID">Pascal:14-0010513</idno><idno type="wicri:Area/PascalFrancis/Corpus">000631</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study</title><author><name sortKey="Thomas, Nancy E" sort="Thomas, Nancy E" uniqKey="Thomas N" first="Nancy E." last="Thomas">Nancy E. Thomas</name><affiliation><inist:fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Busam, Klaus J" sort="Busam, Klaus J" uniqKey="Busam K" first="Klaus J." last="Busam">Klaus J. Busam</name><affiliation><inist:fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="From, Lynn" sort="From, Lynn" uniqKey="From L" first="Lynn" last="From">Lynn From</name><affiliation><inist:fA14 i1="03"><s1>Women's College Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kricker, Anne" sort="Kricker, Anne" uniqKey="Kricker A" first="Anne" last="Kricker">Anne Kricker</name><affiliation><inist:fA14 i1="05"><s1>The University of Sydney</s1><s2>Sydney, New South Wales</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Armstrong, Bruce K" sort="Armstrong, Bruce K" uniqKey="Armstrong B" first="Bruce K." last="Armstrong">Bruce K. Armstrong</name><affiliation><inist:fA14 i1="05"><s1>The University of Sydney</s1><s2>Sydney, New South Wales</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Anton Culver, Hoda" sort="Anton Culver, Hoda" uniqKey="Anton Culver H" first="Hoda" last="Anton-Culver">Hoda Anton-Culver</name><affiliation><inist:fA14 i1="07"><s1>University of California</s1><s2>Irvine</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gruber, Stephen B" sort="Gruber, Stephen B" uniqKey="Gruber S" first="Stephen B." last="Gruber">Stephen B. Gruber</name><affiliation><inist:fA14 i1="08"><s1>University of Southern California</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gallagher, Richard P" sort="Gallagher, Richard P" uniqKey="Gallagher R" first="Richard P." last="Gallagher">Richard P. Gallagher</name><affiliation><inist:fA14 i1="04"><s1>British Columbia Cancer Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zanetti, Roberto" sort="Zanetti, Roberto" uniqKey="Zanetti R" first="Roberto" last="Zanetti">Roberto Zanetti</name><affiliation><inist:fA14 i1="09"><s1>Center for Cancer Prevention</s1><s2>Torino</s2><s3>ITA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rosso, Stefano" sort="Rosso, Stefano" uniqKey="Rosso S" first="Stefano" last="Rosso">Stefano Rosso</name><affiliation><inist:fA14 i1="09"><s1>Center for Cancer Prevention</s1><s2>Torino</s2><s3>ITA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dwyer, Terence" sort="Dwyer, Terence" uniqKey="Dwyer T" first="Terence" last="Dwyer">Terence Dwyer</name><affiliation><inist:fA14 i1="10"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Venn, Alison" sort="Venn, Alison" uniqKey="Venn A" first="Alison" last="Venn">Alison Venn</name><affiliation><inist:fA14 i1="06"><s1>Menzies Research Institute</s1><s2>Tasmania</s2><s3>AUS</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kanetsky, Peter A" sort="Kanetsky, Peter A" uniqKey="Kanetsky P" first="Peter A." last="Kanetsky">Peter A. Kanetsky</name><affiliation><inist:fA14 i1="11"><s1>University of Pennsylvania</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Groben, Pamela A" sort="Groben, Pamela A" uniqKey="Groben P" first="Pamela A." last="Groben">Pamela A. Groben</name><affiliation><inist:fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Honglin Hao" sort="Honglin Hao" uniqKey="Honglin Hao" last="Honglin Hao">HONGLIN HAO</name><affiliation><inist:fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Orlow, Irene" sort="Orlow, Irene" uniqKey="Orlow I" first="Irene" last="Orlow">Irene Orlow</name><affiliation><inist:fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Reiner, Anne S" sort="Reiner, Anne S" uniqKey="Reiner A" first="Anne S." last="Reiner">Anne S. Reiner</name><affiliation><inist:fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Li Luo" sort="Li Luo" uniqKey="Li Luo" last="Li Luo">LI LUO</name><affiliation><inist:fA14 i1="12"><s1>University of New Mexico</s1><s2>Albuquerque, NM</s2><s3>USA</s3><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Paine, Susan" sort="Paine, Susan" uniqKey="Paine S" first="Susan" last="Paine">Susan Paine</name><affiliation><inist:fA14 i1="12"><s1>University of New Mexico</s1><s2>Albuquerque, NM</s2><s3>USA</s3><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ollila, David W" sort="Ollila, David W" uniqKey="Ollila D" first="David W." last="Ollila">David W. Ollila</name><affiliation><inist:fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Wilcox, Homer" sort="Wilcox, Homer" uniqKey="Wilcox H" first="Homer" last="Wilcox">Homer Wilcox</name><affiliation><inist:fA14 i1="13"><s1>New Jersey Department of Health</s1><s2>Trenton, NJ</s2><s3>USA</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Begg, Colin B" sort="Begg, Colin B" uniqKey="Begg C" first="Colin B." last="Begg">Colin B. Begg</name><affiliation><inist:fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Berwick, Marianne" sort="Berwick, Marianne" uniqKey="Berwick M" first="Marianne" last="Berwick">Marianne Berwick</name><affiliation><inist:fA14 i1="12"><s1>University of New Mexico</s1><s2>Albuquerque, NM</s2><s3>USA</s3><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Association</term><term>Cancerology</term><term>Environment</term><term>Ethnic origin</term><term>Gene</term><term>Genetics</term><term>Malignant melanoma</term><term>Primary</term><term>Survival</term><term>Tumor infiltrating lymphocyte</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Mélanome malin</term><term>Lymphocyte infiltrant tumeur</term><term>Primaire</term><term>Association</term><term>Origine ethnique</term><term>Survie</term><term>Gène</term><term>Génétique</term><term>Environnement</term><term>Cancérologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. Patients and Methods On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined. Results Independent predictors (P< .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (P<sub>trend</sub> < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage. Conclusion At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0></fA01><fA03 i2="1"><s0>J. clin. oncol.</s0></fA03><fA05><s2>31</s2></fA05><fA06><s2>33</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study</s1></fA08><fA11 i1="01" i2="1"><s1>THOMAS (Nancy E.)</s1></fA11><fA11 i1="02" i2="1"><s1>BUSAM (Klaus J.)</s1></fA11><fA11 i1="03" i2="1"><s1>FROM (Lynn)</s1></fA11><fA11 i1="04" i2="1"><s1>KRICKER (Anne)</s1></fA11><fA11 i1="05" i2="1"><s1>ARMSTRONG (Bruce K.)</s1></fA11><fA11 i1="06" i2="1"><s1>ANTON-CULVER (Hoda)</s1></fA11><fA11 i1="07" i2="1"><s1>GRUBER (Stephen B.)</s1></fA11><fA11 i1="08" i2="1"><s1>GALLAGHER (Richard P.)</s1></fA11><fA11 i1="09" i2="1"><s1>ZANETTI (Roberto)</s1></fA11><fA11 i1="10" i2="1"><s1>ROSSO (Stefano)</s1></fA11><fA11 i1="11" i2="1"><s1>DWYER (Terence)</s1></fA11><fA11 i1="12" i2="1"><s1>VENN (Alison)</s1></fA11><fA11 i1="13" i2="1"><s1>KANETSKY (Peter A.)</s1></fA11><fA11 i1="14" i2="1"><s1>GROBEN (Pamela A.)</s1></fA11><fA11 i1="15" i2="1"><s1>HONGLIN HAO</s1></fA11><fA11 i1="16" i2="1"><s1>ORLOW (Irene)</s1></fA11><fA11 i1="17" i2="1"><s1>REINER (Anne S.)</s1></fA11><fA11 i1="18" i2="1"><s1>LI LUO</s1></fA11><fA11 i1="19" i2="1"><s1>PAINE (Susan)</s1></fA11><fA11 i1="20" i2="1"><s1>OLLILA (David W.)</s1></fA11><fA11 i1="21" i2="1"><s1>WILCOX (Homer)</s1></fA11><fA11 i1="22" i2="1"><s1>BEGG (Colin B.)</s1></fA11><fA11 i1="23" i2="1"><s1>BERWICK (Marianne)</s1></fA11><fA14 i1="01"><s1>University of North Carolina</s1><s2>Chapel Hill, NC</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>20 aut.</sZ></fA14><fA14 i1="02"><s1>Memorial Sloan-Kettering Cancer Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>17 aut.</sZ><sZ>22 aut.</sZ></fA14><fA14 i1="03"><s1>Women's College Hospital</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>British Columbia Cancer Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>8 aut.</sZ></fA14><fA14 i1="05"><s1>The University of Sydney</s1><s2>Sydney, New South Wales</s2><s3>AUS</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Menzies Research Institute</s1><s2>Tasmania</s2><s3>AUS</s3><sZ>12 aut.</sZ></fA14><fA14 i1="07"><s1>University of California</s1><s2>Irvine</s2><s3>USA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="08"><s1>University of Southern California</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="09"><s1>Center for Cancer Prevention</s1><s2>Torino</s2><s3>ITA</s3><sZ>9 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="10"><s1>International Agency for Research on Cancer</s1><s2>Lyon</s2><s3>FRA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="11"><s1>University of Pennsylvania</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>13 aut.</sZ></fA14><fA14 i1="12"><s1>University of New Mexico</s1><s2>Albuquerque, NM</s2><s3>USA</s3><sZ>18 aut.</sZ><sZ>19 aut.</sZ><sZ>23 aut.</sZ></fA14><fA14 i1="13"><s1>New Jersey Department of Health</s1><s2>Trenton, NJ</s2><s3>USA</s3><sZ>21 aut.</sZ></fA14><fA20><s1>4252-4259</s1></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20094</s2><s5>354000507427000120</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>34 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0010513</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Purpose Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. Patients and Methods On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined. Results Independent predictors (P< .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (P<sub>trend</sub> < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage. Conclusion At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions.</s0></fC01><fC02 i1="01" i2="X"><s0>002B04C</s0></fC02><fC02 i1="02" i2="X"><s0>002B08A</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Mélanome malin</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Malignant melanoma</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Melanoma maligno</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Lymphocyte infiltrant tumeur</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Tumor infiltrating lymphocyte</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Linfocito infiltrando tumor</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Primaire</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Primary</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Primario</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Association</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Association</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Asociación</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Origine ethnique</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Ethnic origin</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Origen étnico</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Survie</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Survival</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Sobrevivencia</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Gène</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Gene</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Gen</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Génétique</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Genetics</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Genética</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Environnement</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Environment</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Medio ambiente</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cancérologie</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Cancerology</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cancerología</s0><s5>17</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fN21><s1>006</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 14-0010513 INIST</NO><ET>Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study</ET><AU>THOMAS (Nancy E.); BUSAM (Klaus J.); FROM (Lynn); KRICKER (Anne); ARMSTRONG (Bruce K.); ANTON-CULVER (Hoda); GRUBER (Stephen B.); GALLAGHER (Richard P.); ZANETTI (Roberto); ROSSO (Stefano); DWYER (Terence); VENN (Alison); KANETSKY (Peter A.); GROBEN (Pamela A.); HONGLIN HAO; ORLOW (Irene); REINER (Anne S.); LI LUO; PAINE (Susan); OLLILA (David W.); WILCOX (Homer); BEGG (Colin B.); BERWICK (Marianne)</AU><AF>University of North Carolina/Chapel Hill, NC/Etats-Unis (1 aut., 14 aut., 15 aut., 20 aut.); Memorial Sloan-Kettering Cancer Center/New York, NY/Etats-Unis (2 aut., 16 aut., 17 aut., 22 aut.); Women's College Hospital/Toronto, Ontario/Canada (3 aut.); British Columbia Cancer Research Centre/Vancouver, British Columbia/Canada (8 aut.); The University of Sydney/Sydney, New South Wales/Australie (4 aut., 5 aut.); Menzies Research Institute/Tasmania/Australie (12 aut.); University of California/Irvine/Etats-Unis (6 aut.); University of Southern California/Los Angeles, CA/Etats-Unis (7 aut.); Center for Cancer Prevention/Torino/Italie (9 aut., 10 aut.); International Agency for Research on Cancer/Lyon/France (11 aut.); University of Pennsylvania/Philadelphia, PA/Etats-Unis (13 aut.); University of New Mexico/Albuquerque, NM/Etats-Unis (18 aut., 19 aut., 23 aut.); New Jersey Department of Health/Trenton, NJ/Etats-Unis (21 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Journal of clinical oncology; ISSN 0732-183X; Etats-Unis; Da. 2013; Vol. 31; No. 33; Pp. 4252-4259; Bibl. 34 ref.</SO><LA>Anglais</LA><EA>Purpose Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. Patients and Methods On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined. Results Independent predictors (P< .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (P<sub>trend</sub> < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage. Conclusion At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions.</EA><CC>002B04C; 002B08A</CC><FD>Mélanome malin; Lymphocyte infiltrant tumeur; Primaire; Association; Origine ethnique; Survie; Gène; Génétique; Environnement; Cancérologie</FD><FG>Tumeur maligne; Cancer</FG><ED>Malignant melanoma; Tumor infiltrating lymphocyte; Primary; Association; Ethnic origin; Survival; Gene; Genetics; Environment; Cancerology</ED><EG>Malignant tumor; Cancer</EG><SD>Melanoma maligno; Linfocito infiltrando tumor; Primario; Asociación; Origen étnico; Sobrevivencia; Gen; Genética; Medio ambiente; Cancerología</SD><LO>INIST-20094.354000507427000120</LO><ID>14-0010513</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000631 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000631 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:14-0010513
|texte= Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
}}
| This area was generated with Dilib version V0.6.33. |  |